Printer Friendly

TELIOS FILES IND FOR ANTI-THROMBOTIC PEPTIDE, TP-9201

 SAN DIEGO, Nov. 1 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for its platelet aggregation inhibitor, TP-9201. Preclinical studies conducted by several groups of independent researchers suggest that TP-9201 may have significant benefits over other platelet-directed anti- thrombotic therapies on the market or in development. Studies in animal models indicate that TP-9201 is fast-acting, reversible, non- immunogenic, and inhibits blood clotting without increasing bleeding time. Telios' clinical trials are designed to determine whether these beneficial effects can be substantiated in humans. Telios plans to begin Phase I clinical trials of TP-9201 in healthy volunteers in early 1994.
 Platelet activation and aggregation are critical components of serious vascular incidents including heart attack, unstable angina, abrupt vessel occlusion after surgery, restenosis after angioplasty, and stroke. Platelet-rich clots can lead to secondary heart attacks after thrombolytic therapy with t-PA or streptokinase. TP-9201, a synthetic cyclic peptide containing the arginine-glycine-aspartic acid (RGD) cell adhesion sequence, is designed to inhibit platelet aggregation by specifically blocking fibrinogen receptors on platelets.
 Preclinical studies of TP-9201 conducted in conjunction with Dr. Benedict Lucchesi of the University of Michigan Medical School and his associates were recently published in an article entitled "Inhibition Of Coronary Artery Reocclusion After Thrombolysis With An RGD-Containing Peptide With No Significant Effect On Bleeding Time" in the September 1993 issue of Coronary Artery Disease. The authors conclude that the apparent lack of bleeding side-effects provides TP-9201 with the opportunity to be used as an adjunct to thrombolytic therapy, including applications in patients who are not currently eligible for treatment due to perceived increased risk of hemorrhage. The use of TP-9201 may also permit reduction of the thrombolytic dose, thus reducing the hemorrhagic risk.
 The authors also propose that, "Reduction of rethrombosis achieved by TP-9201 treatment may also translate into reduction in the need for secondary intervention such as angioplasty or cardiopulmonary bypass, or it may result in an improvement of cardiac function and a reduction in infarct size. Also, the efficacy of thrombolytic therapy in otherwise non-responsive patients may be increased."
 Other products that permanently disable platelets can lead to thrombocytopenia (a decrease in platelet count) and increased template bleeding time, a potentially detrimental side-effect that can result in internal bleeding and hemorrhage. The authors state that although it has been recently reported that template bleeding time does not correlate with bleeding events in a patient population receiving monoclonal antibody therapy, the potential problems of surgical bleeding and blood loss caused by irreversible fibrinogen receptor blockage have not been addressed. These effects can only be neutralized by the slow formation of new platelets or a transfusion.
 Telios is a leader in the development of "matrix medicine" -- a new class of therapeutic products that modify or mimic extracellular matrix functions in tissue repair and disease. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases (such as certain kidney, liver, and lung diseases), cardiovascular diseases, and osteoporosis. In March 1993, Telios submitted a Pre-Market Approval Application (PMA) to the U.S. FDA for the use of ARGIDENE(TM) Gel in the treatment of diabetic foot ulcers.
 -0- 11/1/93
 /CONTACT: Audrey D. Keane, director of corporate development, of Telios Pharmaceuticals, 619-622-2615/
 (TLIO)


CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU:

JL-LS -- SD002 -- 8921 11/01/93 07:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1993
Words:577
Previous Article:BRITRAIL TRAVEL LINKS GERMANY AND BRITAIN WITH 1994 'BRITGERMAN RAILPASS,' LATEST DUAL-COUNTRY PASS
Next Article:INTERLINQ NO. 32 ON FORBES MAGAZINE LIST OF BEST 200 SMALL COMPANIES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters